A Comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-Iodine Administered Doses for Recombinant Thyrotropin-Stimulated Postoperative Thyroid Remnant Ablation in Differentiated Thyroid Cancer

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

2006 • 2,021 citations

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

2006 • 1,963 citations

“Proving the null hypothesis” in clinical trials

1982 • 870 citations

Second primary malignancies in thyroid cancer patients

2003 • 623 citations

A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer1

1999 • 555 citations

Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study

2006 • 440 citations

A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer

2004 • 425 citations

Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

2006 • 325 citations

A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer

1999 • 306 citations

Proving the null hypothesis.

1991 • 259 citations

A Comparison of Short-Term Changes in Health-Related Quality of Life in Thyroid Carcinoma Patients Undergoing Diagnostic Evaluation with Recombinant Human Thyrotropin Compared with Thyroid Hormone Withdrawal

2006 • 190 citations

Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report

2005 • 183 citations

Ablation of Thyroid Residues with 30 mCi 131I: A Comparison in Thyroid Cancer Patients Prepared with Recombinant Human TSH or Thyroid Hormone Withdrawal

2002 • 176 citations

Radioiodine Dose for Remnant Ablation in Differentiated Thyroid Carcinoma: A Randomized Clinical Trial in 509 Patients

2004 • 172 citations

Radioiodine Treatment with 30 mCi after Recombinant Human Thyrotropin Stimulation in Thyroid Cancer: Effectiveness for Postsurgical Remnants Ablation and Possible Role of Iodine Content in<scp>l</scp>-Thyroxine in the Outcome of Ablation

2003 • 148 citations

Is the Serum Thyroglobulin Response to Recombinant Human Thyrotropin Sufficient, by Itself, to Monitor for Residual Thyroid Carcinoma?

2002 • 144 citations

Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma

1998 • 139 citations

Combination of Radioiodine (131I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid Carcinoma

1998 • 136 citations

Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer.

1991 • 129 citations

Radioiodine Ablation of Thyroid Remnants After Preparation with Recombinant Human Thyrotropin

2001 • 110 citations

Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy

2000 • 55 citations